medic margin upgrad
equal-weight
gener contribut profit
medic segment upward margin trajectori turn
construct potenti upsid qualiti issu translat
lower api suppli china lead gener inflat
catalyst ny ca opioid trial headlin pt
 distribut unit state america
cardin third largest distributor pharmaceut medic suppli
unit state share under-perform last five
year myriad headwind gener deflat sell side
recent opioid liabil share ytd
outperform decemb quarter beat-and-rais
previou underweight thesi base combin on-going pressur
face independ custom repres downsid margin opioid
liabil impact competit howev consid improv
gener sourc trend medic segment margin expans like
sustain next twelv month increas confid
manag abil deliv guidanc acceler earn trajectori
upgrad equal-weight
gener environ improv gener primari contributor
decemb quarter beat first time year believ trend
sustain support view sign gener product suppli
constraint last month track data point suggest
heighten focu qualiti issu associ china-bas api supplier
could take time resolv could support gener inflationari trend
histor correl margin expans furthermor
potenti suppli issu could exacerb recent coronaviru
outbreak addit step-up new drug schedul lose patent protect
june decemb time period add favor backdrop see
medic segment still earli phase turnaround medic segment
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
profit continu improv cost save initi suppli chain
invest start manifest medic segment
margin repres bp bp y/i margin expans
low dec quarter near-term cardin focu
address surgic gown recal therefor step-up margin expans
may measur model medic margin run-rat
bp
estim chang rais price target rais ep
estim previous compar guidanc
consensu reflect share repurchas higher ebit lower
interest expens new dcf-deriv price target assum mid-
term revenu growth mid-term ebit margin opioid
litig liabil lower wacc assumpt
prior account market condit improv fundament pharma
medic segment translat greater gener warrant lower
equiti risk premium view price target impli ev/ebitda multipl
ebitda adjust opioid liabil share turn
averag ev/ebitda multipl period
distributor benefit gener inflat see exhibit
risk thesi opioid litig continu key overhang model
estim million opioid-rel fee repres headwind
ebit growth continu model total liabil
distributor period estim addit per share drag
everi increment billion settlement payment risk includ
neg impact specialti margin on-going independ store closur
acceler mix shift toward larger lower margin client
upgrad cardin share equal-weight underweight reflect
stabil environ gener improv margin medic segment opioid
litig continu headwind time resolut remain uncertain
price deriv use dcf analysi impli ebitda
estim turn averag ev/ebitda multipl
period compani benefit gener inflat
improv environ around gener drug call manag note
seen sever quarter stabil price environ gener along
continu growth volum new gener drug launch led
posit y/i profit contribut gener first time sever quarter
believ trend sustain expect continu posit y/i profit
contribut gener busi due on-going gener product suppli
constraint new gener introduct
exhibit y/i chang gener drug price base ms weight basket
ms gener price tracker captur improv trend base analysi gener
price deflat improv calendar annual cumul deflat level
compar drug basket exhibit
decemb quarter track gener product price declin
gener product price increas compar declin increas
septemb quarter decemb year ago y/i basi
track deflat quarter vs previou quarter
period last year
look toward commentari recent industri confer teva gener
manufactur also point stabl price environ price
stabil death spiral bottom got ignit fda approv
anda engin chines player get marketplac teva ceo kre
schultz earn call also point competit stabl sell-sid
base case assum continu stabil gener environ bull
exhibit drug lose patent protect align cardin fiscal
brand drug patent cliff
total market
gener market convers
total market
gener market convers
new gener launch benefit distributor result well estim
meaning step brand gener convers june decemb
period benefit pend launch sprycel chantix dexil
tak atripla estim gener launch could repres
billion total retail opportun year roll basi year
year impli sequenti tailwind distributor exhibit
medic segment trend point turnaround
cost-cut invest within medic segment led improv
margin first two quarter manag discuss on-going
invest medic segment includ streamlin distribut network
enhanc gtm strategi ration footprint progress in-lin
expect addit begin see result on-going cost save
initi target million year million
medic segment margin respect well histor
margin adjust million
charg addit low-end guidanc ldd growth medic
segment ebit impli margin least point turnaround medic
segment trend refer model margin
near-term cardin deploy medic segment team address
concern custom patient may affect surgic gown recal
manag recogn may slow progress commerci suppli
chain initi continu emphas underli strategi work
exhibit medic segment revenu ebit profit trend
encourag discuss opioid suggest resolut may work
on-going opioid litig remain issu three distributor recent commentari
around continu progress discuss state attorney gener around
global settlement framework encourag addit
cardin comment state work encompass us state
within global framework provid counti citi involv
multi-district lawsuit incent also agre framework time
resolut remain uncertain process involv multi-later discuss
need take place defend repres variou state
counti jurisdict suggest longer time frame ultim resolut
model assum total liabil distributor period
impli across distributor cardin reserv
addit model increas opioid-rel cost flow thru pharma
segment million expens million
bear case assum addit share headwind opioid litig
catalyst watch next month new york california state trial
state defend mdl continu work bring global
framework state counti citi order gain wider accept
calendar opioids-rel trial continu spring beyond two
largest near-term upcom catalyst state trial schedul new york
california
peopl state new york purdu pharma et al
peopl state california purdu pharma et al orang counti superior court
santa ana california
state ohio ex rel mike dewin capac attorney gener state ohio
mckesson corpor et al court common plea madison counti ohio
state alabama purdu pharma et al circuit court montgomeri counti alabama
state mississippi purdu pharma et al chanceri court first judici district
state louisiana purdu pharma et al judici district court parish
east baton roug state louisiana
state ohio ex rel mike dewin ohio attorney gener purdu pharma et
al common plea court ross counti ohio
state washington mckesson drug corp et al superior court king counti washington
state arkansa et al purdu pharma et al circuit court crittenden counti
texa opioid litig district court harri counti texa
state alaska purdu pharma superior court state alaska third judici
district anchorag
state missouri ex rel eric schmitt offici capac missouri attorney gener
purdu pharma et al circuit court citi st loui state missouri
shelbi counti shelbi counti board commission purdu pharma circuit
court shelbi counti memphi tennesse
state arizona purdu pharma et al superior court pima counti arizona
state arkansa ex rel lesli rutledg attorney gener purdu pharma et al
circuit court pulaski counti arkansa
state delawar ex rel matthew purdu pharma et al superior court
state delawar
state new mexico purdu pharma et al first judici district counti santa fe
state new mexico
state georgia teva pharmaceut ltd et al superior court gwinnett
crittenden counti crittenden counti et al amerisourcebergen drug corpor et al circuit court
price drug import plan relat rule continu
concern like indirect effect distributor convers
dc consult suggest likelihood relat rule take effect
remain low howev rule implement would impact
distributor custom econom secondari effect translat margin
compress distributor specif within specialti drug distribut
estim among distributor potenti effect price import
would lowest cardin given compani smallest exposur specialti
revenu oper incom estim
suppli issu relat qualiti activ pharmaceut ingredi api could
upsid risk past sever month sever report issu
regard qualiti ingredi come china result believ could
gener price inflat shortag api sourc china exacerb
recent coronaviru concern environ believ cardin could stand
benefit collect higher fee higher-pr gener situat
factor model number compani guidanc
updat model estim reflect beat updat
guidanc well improv trend within gener busi updat
pharma segment ebit guidanc lsd rais prior hsd-ldd
impli billion updat ep guidanc rang
rais prior guidanc assum million interest/oth
expens waso million
million
revenu increas
revenu estim million million
million respect billion billion
billion reflect continu improv trend
pharma medic segment
increas million
million million respect reflect
increas revenu oper margin remain
rel consist prior estim improv
trend gener medic partial off-set
segment increas corporate-level invest
margin improv bp compani begin lap
invest expens
ep ep estim increas
prior near midpoint guidanc
ep estim increas
respect estim move reflect share
repurchas higher ebit margin lower interest
increas pt dcf-base price target
bull case valuat bear case valuat
base impli ev/ebitda multipl base case ebitda
estim adjust opioid liabil multipl
turn averag ev/ebitda multipl period
distributor benefit gener inflat see exhibit
bull appli ev/ebitda multipl bull case
ebitda estim adjust opioid liabil
multipl in-lin maximum ev/ebitda multipl
period distributor benefit gener inflat
bear appli ev/ebitda multipl bear case
ebitda estim adjust opioid liabil
multipl in-lin forward ev/ebitda multipl last
reflect weak brand inflat trend higher opioid liabil higher gener
exhibit ev/ebitda multipl distributor
detail break-out dcf-base price target chang refer exhibit bridg
price target chang refer exhibit detail look dcf
dcf-base price target increas due higher
revenu growth estim medium-term
mid-term wacc
decreas prior due market condit
well lower assumpt equiti risk premium
account improv fundament gener
decreas share count result ytd share
partial off-set drag nwc requir
invest support specialti growth
 tax ebit
adjust tax-effect ebit
revenue
revenue
 chang nwc
growth nwc
growth leas expens
pv
discount rate debt
equiti
debt tax
debt tax
present valu without opioid
present valu termin valu without opioid
termin valu total
present valu opioid liabil
growth nwc
note outsiz price increas defin price increas greater
gener price tracker base wac averag wac price data basket gener drug go back price detail pars differ dosag form gener basket track uniqu ndc/upc code encompass nearli total gener revenu gener
volum exclud analysi gener drug current fda drug shortag list outsiz price increas inflat add would favor benefit trend bp
stabl gener environ improv medic segment
dcf-deriv base case price assum termin growth wacc
addit assum global opioid litig settlement estim
could respons
cardin third largest drug
distributor oper segment drug
distribut ebit medic
suppli ebit
improv price trend gener
busi along volum growth
new product launch led sever
quarter stabil y/i growth
gener oper prot rst time
margin stabil improv
medic segment could signal
turnaround busi
continu risk moder brand
renew loss custom discount
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
impli multipl averag
yr forward ev/ebitda multipl past
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
impli multipl modestli
averag forward ev/ebitda multipl
past year
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
impli multipl modestli
minimum forward ev/ebitda multipl
gener manufactur commentari gener
news ow opioid litig settlement
view explan region hierarchi
research highest favor quintil
increas brand inat
gener inat due suppli shortag
growth accel specialti drug distribut
servic
introduct rule
slowdown brand inat deterior
continu price pressur margin eros
increas opioid legal settlement payment
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
valuat methodolog risk
growth wacc addit assum global opioid litig
settlement estim respons
risk upsid
increas brand inflat
acceler growth specialti drug distribut servic
risk downsid
signific slowdown brand inflat
deterior gener price deflat
continu price pressur margin eros within independ pharmaci
increas opioid legal settlement payment
termin growth rate mid-term ebit margin wacc addit
assum global opioid litig settlement estim mckesson
respons
risk upsid
increas brand inflat
acceler growth specialti drug distribut servic
reimburs headwind europ abat
risk downsid
signific slowdown brand inflat
deterior gener price deflat
continu price pressur margin eros within independ pharmaci
increas opioid legal settlement payment
pt base ev/ebitda discount gener peer averag
project ebitda compound-annual-growth-rate
risk upsid
propos global opioid settlement final
flow forecast
risk downsid
